InsidersTradesSigma
HLB이노베이션 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the HLB이노베이션 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, HLB이노베이션 has published 77 public disclosures. Market capitalisation: €369.5bn. The latest transaction was filed on 7 July 2026 (Other). Among the most active insiders: HLB. All data is free.
77
Insider Decl.
0
Thresholds
€8m
33 ops.
Buy Volume
€559m
6 ops.
Sell Volume
38Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,170 of 25,484 companies
16.1
score / 100
Value17
Quality15
FCF yld-8.4%
Earn yld-9.0%
EV/EBITDA·
ROE-15%
Gross mgn13%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations77 total
ShareKRXDART:20260511000381
25 of 77 declarations
About HLB이노베이션
HLB이노베이션 is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative solutions in the pharmaceutical field.